https://orcid.org/0000-0002-2119-5447
![Sample our Health and Social Care journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5938/TOC-Subject-Sample-2021-Health-Social-Care.jpg"})
Abstract
Aim: To evaluate the value of combined detection of plasma cfDNA concentration and integrity in the early diagnosis of NSCLC. Methods: Real-time fluorescence quantitative PCR was used to determine the concentration and integrity of plasma cfDNA in 71 NSCLC patients and 53 healthy people. Results: Combined detection of plasma cfDNA concentration and integrity had higher diagnostic power in differentiating NSCLC patients with stage I/II from healthy people than detection of plasma cfDNA concentration alone or integrity alone. The AUC, sensitivity and specificity of the combined detection of plasma cfDNA concentration and integrity were 0.781, 0.62 and 0.85. Conclusion: Combined detection of plasma cfDNA concentration and integrity could improve the diagnostic value in NSCLC detection.
Plain language summary
The discovery of cfDNA has opened up a wide range of new possibilities for the diagnosis of cancer. CfDNA provides a noninvasive diagnostic approach for early screening, early detection and monitoring of patients with cancer. Currently, the application of cfDNA in clinical practice for NSCLC patients has been widely reported, which mainly focused on DNA methylation detection, oncogenic driver gene mutation detection. However, few studies have evaluated the diagnostic value of combined detection of plasma cfDNA concentration and integrity for NSCLC patients. Our study suggests that the combination of plasma cfDNA concentration and integrity has higher AUC value in differentiating NSCLC patients from healthy individuals than plasma cfDNA concentration alone or integrity alone.
The concentration of LINE1-97 fragment was significantly higher in NSCLC patients than that of healthy controls.
The concentration of LINE1-266 fragment was significantly higher in NSCLC patients than that of healthy controls.
The AUC of ROC curve for distinguishing NSCLC patients with stage I/II from healthy controls by the combination of LINE1-97 + LINE1-266 was 0.781.
Plasma cfDNA integrity LINE1-266/97 were significantly lower in NSCLC patients with stage I/II and stage III/IV than in healthy controls.
The AUC of ROC curve for distinguishing NSCLC patients with stage I/II from healthy controls by LINE1-97 + LINE1-266 + LINE1-266/97 was 0.781.
Combined detection of plasma cfDNA concentration and integrity can significantly improve the accuracy of NSCLC early detection.
Author contributions
Q Huang was responsible for study conception and design; S Ren and C Yu were responsible for specimen collection; S Ren and C Yu were responsible for conducting experiments and data analysis, S Ren and Q Huang were responsible for drafting and revision of the manuscript.
Financial disclosure
This study was partly supported by the National Natural Science Foundation of China (82172370), Clinical Medical Research Project of Army Medical University (2019XLC1010), Chongqing Key Clinical Specialties project, Excellent Talent Project of Army Medical University, Chongqing medical scientific research project (No. 2022QNXM036). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Competing interests disclosure
The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Writing disclosure
No writing assistance was utilized in the production of this manuscript.
Ethical conduct of research
This study was approved by the Medical Ethics Committee of Daping Hospital of Army Medical University and was carried out according to the relevant guidelines and regulations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.